Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...
A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...
The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...
MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...
Ionis Pharmaceuticals (IONS) announced that the U.S. FDA has accepted for review the New Drug Application for donidalorsen, an investigational ...
The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...
If approved, donidalorsen would be a first-in-class RNA-targeted medicine for hereditary angioedema. The agency’s goal date ...
The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...
The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...
CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA ...
Medical experts who’ve studied the experimental treatment program, however, say there’s no evidence to support Trump’s claims ...
Click here for a full investment analysis of Cybin Inc., a speculative play on FDA approval for psychedelic-based treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback